Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-26), Pacific Biosciences of California's Beta is 2.7008.
Pacific Biosciences of California (NAS:PACB) Beta Explanation
Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.
Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
Pacific Biosciences of California Beta Related Terms
Pacific Biosciences of California Beta Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Pacific Biosciences of California's Beta, along with its competitors' market caps and Beta data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pacific Biosciences of California Beta vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pacific Biosciences of California's Beta distribution charts can be found below:
* The bar in red indicates where Pacific Biosciences of California's Beta falls into.
Pacific Biosciences of California Beta Calculation
Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.
Pacific Biosciences of California (PACB) has a Beta of 2.7008 as of Jun. 26, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Pacific Biosciences of California and its competitors.
Is Pacific Biosciences of California's Beta too high?
Pacific Biosciences of California's current Beta is 2.7008. Overall, Pacific Biosciences of California has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pacific Biosciences of California's Beta compare to CATX and LAB?
Pacific Biosciences of California's Beta of 2.7008 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Medical Devices & Instruments company?
A good Beta depends on the Medical Devices & Instruments industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Pacific Biosciences of California and its competitors. Pacific Biosciences of California's current Beta is 2.7008. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacific Biosciences of California stock overvalued right now?
Based on GuruFocus' analysis, Pacific Biosciences of California (PACB) is currently considered Fairly Valued. The stock's GF Value™ is $1.62, compared to a current price of $1.60 — trading 1.2% below its estimated fair value. The current Beta is 2.7008. Pacific Biosciences of California's overall GF Score™ is 53/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Pacific Biosciences of California (PACB), the current Beta is 2.7008 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pacific Biosciences of California (PACB) Overvalued in 2026?
Based on GuruFocus' analysis, Pacific Biosciences of California stock appears to be undervalued.
The current stock price of $1.60 is trading 1.2% below its estimated GF Value™ of $1.62.
GuruFocus considers Pacific Biosciences of California to be Fairly Valued.
Key valuation signals for PACB:
Beta: 2.7008
GF Value™: $1.62 vs. price of $1.60 (1.2% below fair value)
No single metric tells the full story. See the PACB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pacific Biosciences of California Business Description
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.
53GF Score
Get the complete analysis for PACB
Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PACB has been successfully added to your 
